Literature DB >> 22144499

Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

Nasim Mavaddat1, Daniel Barrowdale, Irene L Andrulis, Susan M Domchek, Diana Eccles, Heli Nevanlinna, Susan J Ramus, Amanda Spurdle, Mark Robson, Mark Sherman, Anna Marie Mulligan, Fergus J Couch, Christoph Engel, Lesley McGuffog, Sue Healey, Olga M Sinilnikova, Melissa C Southey, Mary Beth Terry, David Goldgar, Frances O'Malley, Esther M John, Ramunas Janavicius, Laima Tihomirova, Thomas V O Hansen, Finn C Nielsen, Ana Osorio, Alexandra Stavropoulou, Javier Benítez, Siranoush Manoukian, Bernard Peissel, Monica Barile, Sara Volorio, Barbara Pasini, Riccardo Dolcetti, Anna Laura Putignano, Laura Ottini, Paolo Radice, Ute Hamann, Muhammad U Rashid, Frans B Hogervorst, Mieke Kriege, Rob B van der Luijt, Susan Peock, Debra Frost, D Gareth Evans, Carole Brewer, Lisa Walker, Mark T Rogers, Lucy E Side, Catherine Houghton, JoEllen Weaver, Andrew K Godwin, Rita K Schmutzler, Barbara Wappenschmidt, Alfons Meindl, Karin Kast, Norbert Arnold, Dieter Niederacher, Christian Sutter, Helmut Deissler, Doroteha Gadzicki, Sabine Preisler-Adams, Raymonda Varon-Mateeva, Ines Schönbuchner, Heidrun Gevensleben, Dominique Stoppa-Lyonnet, Muriel Belotti, Laure Barjhoux, Claudine Isaacs, Beth N Peshkin, Trinidad Caldes, Miguel de la Hoya, Carmen Cañadas, Tuomas Heikkinen, Päivi Heikkilä, Kristiina Aittomäki, Ignacio Blanco, Conxi Lazaro, Joan Brunet, Bjarni A Agnarsson, Adalgeir Arason, Rosa B Barkardottir, Martine Dumont, Jacques Simard, Marco Montagna, Simona Agata, Emma D'Andrea, Max Yan, Stephen Fox, Timothy R Rebbeck, Wendy Rubinstein, Nadine Tung, Judy E Garber, Xianshu Wang, Zachary Fredericksen, Vernon S Pankratz, Noralane M Lindor, Csilla Szabo, Kenneth Offit, Rita Sakr, Mia M Gaudet, Christian F Singer, Muy-Kheng Tea, Christine Rappaport, Phuong L Mai, Mark H Greene, Anna Sokolenko, Evgeny Imyanitov, Amanda Ewart Toland, Leigha Senter, Kevin Sweet, Mads Thomassen, Anne-Marie Gerdes, Torben Kruse, Maria Caligo, Paolo Aretini, Johanna Rantala, Anna von Wachenfeld, Karin Henriksson, Linda Steele, Susan L Neuhausen, Robert Nussbaum, Mary Beattie, Kunle Odunsi, Lara Sucheston, Simon A Gayther, Kate Nathanson, Jenny Gross, Christine Walsh, Beth Karlan, Georgia Chenevix-Trench, Douglas F Easton, Antonis C Antoniou.   

Abstract

BACKGROUND: Previously, small studies have found that BRCA1 and BRCA2 breast tumors differ in their pathology. Analysis of larger datasets of mutation carriers should allow further tumor characterization.
METHODS: We used data from 4,325 BRCA1 and 2,568 BRCA2 mutation carriers to analyze the pathology of invasive breast, ovarian, and contralateral breast cancers.
RESULTS: There was strong evidence that the proportion of estrogen receptor (ER)-negative breast tumors decreased with age at diagnosis among BRCA1 (P-trend = 1.2 × 10(-5)), but increased with age at diagnosis among BRCA2, carriers (P-trend = 6.8 × 10(-6)). The proportion of triple-negative tumors decreased with age at diagnosis in BRCA1 carriers but increased with age at diagnosis of BRCA2 carriers. In both BRCA1 and BRCA2 carriers, ER-negative tumors were of higher histologic grade than ER-positive tumors (grade 3 vs. grade 1; P = 1.2 × 10(-13) for BRCA1 and P = 0.001 for BRCA2). ER and progesterone receptor (PR) expression were independently associated with mutation carrier status [ER-positive odds ratio (OR) for BRCA2 = 9.4, 95% CI: 7.0-12.6 and PR-positive OR = 1.7, 95% CI: 1.3-2.3, under joint analysis]. Lobular tumors were more likely to be BRCA2-related (OR for BRCA2 = 3.3, 95% CI: 2.4-4.4; P = 4.4 × 10(-14)), and medullary tumors BRCA1-related (OR for BRCA2 = 0.25, 95% CI: 0.18-0.35; P = 2.3 × 10(-15)). ER-status of the first breast cancer was predictive of ER-status of asynchronous contralateral breast cancer (P = 0.0004 for BRCA1; P = 0.002 for BRCA2). There were no significant differences in ovarian cancer morphology between BRCA1 and BRCA2 carriers (serous: 67%; mucinous: 1%; endometrioid: 12%; clear-cell: 2%). CONCLUSIONS/IMPACT: Pathologic characteristics of BRCA1 and BRCA2 tumors may be useful for improving risk-prediction algorithms and informing clinical strategies for screening and prophylaxis.

Entities:  

Mesh:

Year:  2011        PMID: 22144499      PMCID: PMC3272407          DOI: 10.1158/1055-9965.EPI-11-0775

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  45 in total

1.  A BRCA1 nonsense mutation causes exon skipping.

Authors:  S Mazoyer; N Puget; L Perrin-Vidoz; H T Lynch; O M Serova-Sinilnikova; G M Lenoir
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

2.  Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.

Authors:  J E Armes; L Trute; D White; M C Southey; F Hammet; A Tesoriero; A M Hutchins; G S Dite; M R McCredie; G G Giles; J L Hopper; D J Venter
Journal:  Cancer Res       Date:  1999-04-15       Impact factor: 12.701

3.  Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.

Authors:  José Palacios; Emiliano Honrado; Ana Osorio; Alicia Cazorla; David Sarrió; Alicia Barroso; Sandra Rodríguez; Juan C Cigudosa; Orland Diez; Carmen Alonso; Enrique Lerma; Joaquín Dopazo; Carmen Rivas; Javier Benítez
Journal:  Breast Cancer Res Treat       Date:  2005-03       Impact factor: 4.872

4.  Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women.

Authors:  S E Karp; P N Tonin; L R Bégin; J J Martinez; J C Zhang; M N Pollak; W D Foulkes
Journal:  Cancer       Date:  1997-08-01       Impact factor: 6.860

5.  A comparison of bilateral breast cancers in BRCA carriers.

Authors:  Jeffrey N Weitzel; Mark Robson; Barbara Pasini; Siranoush Manoukian; Dominique Stoppa-Lyonnet; Henry T Lynch; Jane McLennan; William D Foulkes; Teresa Wagner; Nadine Tung; Parviz Ghadirian; Olufunmilayo Olopade; Claudine Isaacs; Charmaine Kim-Sing; Pal Møller; Susan L Neuhausen; Kelly Metcalfe; Ping Sun; Steven A Narod
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-06       Impact factor: 4.254

6.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.

Authors:  S R Lakhani; J Jacquemier; J P Sloane; B A Gusterson; T J Anderson; M J van de Vijver; L M Farid; D Venter; A Antoniou; A Storfer-Isser; E Smyth; C M Steel; N Haites; R J Scott; D Goldgar; S Neuhausen; P A Daly; W Ormiston; R McManus; S Scherneck; B A Ponder; D Ford; J Peto; D Stoppa-Lyonnet; Y J Bignon; J P Struewing; N K Spurr; D T Bishop; J G Klijn; P Devilee; C J Cornelisse; C Lasset; G Lenoir; R B Barkardottir; V Egilsson; U Hamann; J Chang-Claude; H Sobol; B Weber; M R Stratton; D F Easton
Journal:  J Natl Cancer Inst       Date:  1998-08-05       Impact factor: 13.506

7.  The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study.

Authors:  J E Armes; A J Egan; M C Southey; G S Dite; M R McCredie; G G Giles; J L Hopper; D J Venter
Journal:  Cancer       Date:  1998-12-01       Impact factor: 6.860

8.  Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes.

Authors:  N Loman; O Johannsson; P O Bendahl; A Borg; M Fernö; H Olsson
Journal:  Cancer       Date:  1998-07-15       Impact factor: 6.860

9.  Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.

Authors:  Sunil R Lakhani; Jorge S Reis-Filho; Laura Fulford; Frederique Penault-Llorca; Marc van der Vijver; Suzanne Parry; Timothy Bishop; Javier Benitez; Carmen Rivas; Yves-Jean Bignon; Jenny Chang-Claude; Ute Hamann; Cees J Cornelisse; Peter Devilee; Matthias W Beckmann; Carolin Nestle-Krämling; Peter A Daly; Neva Haites; Jenny Varley; Fiona Lalloo; Gareth Evans; Christine Maugard; Hanne Meijers-Heijboer; Jan G M Klijn; Edith Olah; Barry A Gusterson; Silvana Pilotti; Paolo Radice; Siegfried Scherneck; Hagay Sobol; Jocelyne Jacquemier; Teresa Wagner; Julian Peto; Michael R Stratton; Lesley McGuffog; Douglas F Easton
Journal:  Clin Cancer Res       Date:  2005-07-15       Impact factor: 12.531

10.  Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families.

Authors:  Hannaleena Eerola; Päivi Heikkilä; Anitta Tamminen; Kristiina Aittomäki; Carl Blomqvist; Heli Nevanlinna
Journal:  Breast Cancer Res       Date:  2005-04-21       Impact factor: 6.466

View more
  179 in total

1.  Targeting progesterone signaling prevents metastatic ovarian cancer.

Authors:  Olga Kim; Eun Young Park; Sun Young Kwon; Sojin Shin; Robert E Emerson; Yong-Hyun Shin; Francesco J DeMayo; John P Lydon; Donna M Coffey; Shannon M Hawkins; Lawrence A Quilliam; Dong-Joo Cheon; Facundo M Fernández; Kenneth P Nephew; Adam R Karpf; Martin Widschwendter; Anil K Sood; Robert C Bast; Andrew K Godwin; Kathy D Miller; Chi-Heum Cho; Jaeyeon Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-01       Impact factor: 11.205

Review 2.  [Diagnosis of breast diseases in a certified breast center].

Authors:  Markus Müller-Schimpfle; Nicole Herröder; Petra Hödl
Journal:  Radiologe       Date:  2021-01-06       Impact factor: 0.635

Review 3.  Identifying Epistasis in Cancer Genomes: A Delicate Affair.

Authors:  Joris van de Haar; Sander Canisius; Michael K Yu; Emile E Voest; Lodewyk F A Wessels; Trey Ideker
Journal:  Cell       Date:  2019-05-30       Impact factor: 41.582

4.  Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.

Authors:  Alison M Dunning; Kyriaki Michailidou; Karoline B Kuchenbaecker; Deborah Thompson; Juliet D French; Jonathan Beesley; Catherine S Healey; Siddhartha Kar; Karen A Pooley; Elena Lopez-Knowles; Ed Dicks; Daniel Barrowdale; Nicholas A Sinnott-Armstrong; Richard C Sallari; Kristine M Hillman; Susanne Kaufmann; Haran Sivakumaran; Mahdi Moradi Marjaneh; Jason S Lee; Margaret Hills; Monika Jarosz; Suzie Drury; Sander Canisius; Manjeet K Bolla; Joe Dennis; Qin Wang; John L Hopper; Melissa C Southey; Annegien Broeks; Marjanka K Schmidt; Artitaya Lophatananon; Kenneth Muir; Matthias W Beckmann; Peter A Fasching; Isabel Dos-Santos-Silva; Julian Peto; Elinor J Sawyer; Ian Tomlinson; Barbara Burwinkel; Frederik Marme; Pascal Guénel; Thérèse Truong; Stig E Bojesen; Henrik Flyger; Anna González-Neira; Jose I A Perez; Hoda Anton-Culver; Lee Eunjung; Volker Arndt; Hermann Brenner; Alfons Meindl; Rita K Schmutzler; Hiltrud Brauch; Ute Hamann; Kristiina Aittomäki; Carl Blomqvist; Hidemi Ito; Keitaro Matsuo; Natasha Bogdanova; Thilo Dörk; Annika Lindblom; Sara Margolin; Veli-Matti Kosma; Arto Mannermaa; Chiu-Chen Tseng; Anna H Wu; Diether Lambrechts; Hans Wildiers; Jenny Chang-Claude; Anja Rudolph; Paolo Peterlongo; Paolo Radice; Janet E Olson; Graham G Giles; Roger L Milne; Christopher A Haiman; Brian E Henderson; Mark S Goldberg; Soo H Teo; Cheng Har Yip; Silje Nord; Anne-Lise Borresen-Dale; Vessela Kristensen; Jirong Long; Wei Zheng; Katri Pylkäs; Robert Winqvist; Irene L Andrulis; Julia A Knight; Peter Devilee; Caroline Seynaeve; Jonine Figueroa; Mark E Sherman; Kamila Czene; Hatef Darabi; Antoinette Hollestelle; Ans M W van den Ouweland; Keith Humphreys; Yu-Tang Gao; Xiao-Ou Shu; Angela Cox; Simon S Cross; William Blot; Qiuyin Cai; Maya Ghoussaini; Barbara J Perkins; Mitul Shah; Ji-Yeob Choi; Daehee Kang; Soo Chin Lee; Mikael Hartman; Maria Kabisch; Diana Torres; Anna Jakubowska; Jan Lubinski; Paul Brennan; Suleeporn Sangrajrang; Christine B Ambrosone; Amanda E Toland; Chen-Yang Shen; Pei-Ei Wu; Nick Orr; Anthony Swerdlow; Lesley McGuffog; Sue Healey; Andrew Lee; Miroslav Kapuscinski; Esther M John; Mary Beth Terry; Mary B Daly; David E Goldgar; Saundra S Buys; Ramunas Janavicius; Laima Tihomirova; Nadine Tung; Cecilia M Dorfling; Elizabeth J van Rensburg; Susan L Neuhausen; Bent Ejlertsen; Thomas V O Hansen; Ana Osorio; Javier Benitez; Rachel Rando; Jeffrey N Weitzel; Bernardo Bonanni; Bernard Peissel; Siranoush Manoukian; Laura Papi; Laura Ottini; Irene Konstantopoulou; Paraskevi Apostolou; Judy Garber; Muhammad Usman Rashid; Debra Frost; Louise Izatt; Steve Ellis; Andrew K Godwin; Norbert Arnold; Dieter Niederacher; Kerstin Rhiem; Nadja Bogdanova-Markov; Charlotte Sagne; Dominique Stoppa-Lyonnet; Francesca Damiola; Olga M Sinilnikova; Sylvie Mazoyer; Claudine Isaacs; Kathleen B M Claes; Kim De Leeneer; Miguel de la Hoya; Trinidad Caldes; Heli Nevanlinna; Sofia Khan; Arjen R Mensenkamp; Maartje J Hooning; Matti A Rookus; Ava Kwong; Edith Olah; Orland Diez; Joan Brunet; Miquel Angel Pujana; Jacek Gronwald; Tomasz Huzarski; Rosa B Barkardottir; Rachel Laframboise; Penny Soucy; Marco Montagna; Simona Agata; Manuel R Teixeira; Sue Kyung Park; Noralane Lindor; Fergus J Couch; Marc Tischkowitz; Lenka Foretova; Joseph Vijai; Kenneth Offit; Christian F Singer; Christine Rappaport; Catherine M Phelan; Mark H Greene; Phuong L Mai; Gad Rennert; Evgeny N Imyanitov; Peter J Hulick; Kelly-Anne Phillips; Marion Piedmonte; Anna Marie Mulligan; Gord Glendon; Anders Bojesen; Mads Thomassen; Maria A Caligo; Sook-Yee Yoon; Eitan Friedman; Yael Laitman; Ake Borg; Anna von Wachenfeldt; Hans Ehrencrona; Johanna Rantala; Olufunmilayo I Olopade; Patricia A Ganz; Robert L Nussbaum; Simon A Gayther; Katherine L Nathanson; Susan M Domchek; Banu K Arun; Gillian Mitchell; Beth Y Karlan; Jenny Lester; Gertraud Maskarinec; Christy Woolcott; Christopher Scott; Jennifer Stone; Carmel Apicella; Rulla Tamimi; Robert Luben; Kay-Tee Khaw; Åslaug Helland; Vilde Haakensen; Mitch Dowsett; Paul D P Pharoah; Jacques Simard; Per Hall; Montserrat García-Closas; Celine Vachon; Georgia Chenevix-Trench; Antonis C Antoniou; Douglas F Easton; Stacey L Edwards
Journal:  Nat Genet       Date:  2016-02-29       Impact factor: 38.330

5.  Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  Joanne Kotsopoulos; Jan Lubinski; Jacek Gronwald; Cezary Cybulski; Rochelle Demsky; Susan L Neuhausen; Charmaine Kim-Sing; Nadine Tung; Susan Friedman; Leigha Senter; Jeffrey Weitzel; Beth Karlan; Pal Moller; Ping Sun; Steven A Narod
Journal:  Int J Cancer       Date:  2014-12-18       Impact factor: 7.396

6.  Impact of familial risk and mammography screening on prognostic indicators of breast disease among women from the Ontario site of the Breast Cancer Family Registry.

Authors:  Meghan J Walker; Lucia Mirea; Kristine Cooper; Mitra Nabavi; Gord Glendon; Irene L Andrulis; Julia A Knight; Frances P O'Malley; Anna M Chiarelli
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

Review 7.  Genetic susceptibility to triple-negative breast cancer.

Authors:  Kristen N Stevens; Celine M Vachon; Fergus J Couch
Journal:  Cancer Res       Date:  2013-03-27       Impact factor: 12.701

Review 8.  Mechanisms of BRCA1 tumor suppression.

Authors:  Daniel P Silver; David M Livingston
Journal:  Cancer Discov       Date:  2012-07-27       Impact factor: 39.397

9.  BRCA 1/2 gene mutation and gastrointestinal stromal tumours: a potential association.

Authors:  Julie Waisbren; Regina Uthe; Kalliopi Siziopikou; Virginia Kaklamani
Journal:  BMJ Case Rep       Date:  2015-07-06

10.  History, biology, and health inequities: emergent embodied phenotypes and the illustrative case of the breast cancer estrogen receptor.

Authors:  Nancy Krieger
Journal:  Am J Public Health       Date:  2012-11-15       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.